Jacalyn Lee faced a wall after her daughter Isla received a diagnosis for a rare genetic condition known as DAND. With no roadmap and limited research available, Lee joined other parents to form The DAND Alliance, determined to find a treatment path. Navigating the complex world of medical research proved difficult for a volunteer-led group, so they sought a partner capable of translating their goals into actionable steps. They turned to Nome, a startup designed to act as a project manager for families navigating rare diseases.
Stevie Ringel, the founder of Nome, built the company based on his own experience with a rare retinal dystrophy. He saw a gap in how small patient organizations manage the jump from fundraising to drug development. Nome functions as a contract research organization that helps families interpret genetic data and create structured plans for potential trials. Their process uses AI to analyze findings quickly, which Ringel believes allows them to provide guidance that would otherwise take months of manual research to compile.
For families, this support creates a clearer sequence of events. Instead of facing a diagnosis with no options, groups receive a detailed report outlining animal studies, trial designs, and necessary vendors. Nome operates with a model that prioritizes speed and affordability, aiming to lower the overall costs of individualized therapies. While the company is in its early stages, it currently manages over ten genetic medicine programs and seeks to automate significant portions of the development workflow as its technology advances.
Ringel views his work as a logistics operation intended to bridge the gap between scientific possibility and patient access. By providing a roadmap, Nome helps families avoid the confusion that often accompanies a rare disease diagnosis. As more groups seek these services, the goal remains to bring down the cost of medicine until treatments become accessible enough for insurance coverage. For parents like Lee, the service offers more than just reports; it provides a way to move from isolation toward potential medical progress.